Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Flowers "leadership" ? IMO, a legacy of self benefit and judgement failures

"Your posts are too long".

I suppose I should be flattered when I see your post that begins with that. You know what they say about imitation! lol

"Wow! The ITC is 'irrelevant' . That knocked the wind out of me."

OK. Slow down. Take a breath. Re-read the post. My feelings = irrelevant, not the ITC, lol.

"It still remains in the BEST INTEREST of TPL and get settlements that are as high as possible."

That sounds good and logical, and in the real world I work in, that seems on the face to be true. But in the world where TPL was allowed (and may still be) to comingle licensing, this is not necessarily true. Signing a multi portfolio license with a company for $15M where $10M is allocated to the MMP and the other $5M to other TPL portfolios may be MORE ATTRACTIVE to TPL than signing a $17M MMP only license.

Do the math, 15% off the top of $17M to TPL is $2.55M. Split the other $14.45M 50/50 with PTSC is $7.225M to TPL. Split that $7.225M 45/55 with Chuck Moore and TPL keeps $3.25M. That means TPL gets $2.55M + $3.25M=$5.8M. In the other scenario, they get $5M+$1.5M+$3.825M=$10.325. Assume they even give 50% of the $5M non MMP revs to the patent owners of the other portfolio and they'd still end up with $7.825M. If you were TPL, which of those 2 scenarios would you pursue?

As for the rest, you're even further imitating my post. See, I've swayed you from a sell and move on admonisher to post as you wish supporter. Welcome to the "darkside", lol. Enjoy you're weekend.

Share
New Message
Please login to post a reply